PADI4 and triple-A syndrome: Pharmacological strategies targeting NETosis—including PAD4 inhibitors (e.g., YW3-56), DNase1, resolvin D1, and PDK inhibitors (e.g., dichloroacetate, DCA)—consistently attenuate AAA progression in preclinical models.